n Cardiovascular Journal of South Africa - New development in HDL : editorial




Extracted from text ... 108 Reduction of low-density lipoprotein cholesterol (LDL-C) is presently the primary focus of lipid-lowering therapy for the prevention and treatment of coronary heart disease (CHD).1-3 However, even with effective LDL-C reduction, the residual risk of major coronary events remains unacceptably high; 70% of patients at risk of myocardial infarction (MI), treated with statin therapy in recent coronary prevention trials, experienced recurrent coronary events.4, 5 Such residual risk reflects our failure on one hand to recognise low plasma levels of high-density lipoprotein cholesterol (HDL-C) as a major independent and predictive cardiovascular risk factor, 6, 7 and on the other, to include ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error